Genetic marker of response to atypical antipsychotics and antidepressants methods for use thereof

摘要

The invention provides methods of identifying candidate psychiatric patients, or patients with movement disorder, for treatment with receptor site or increases density of D2 dopamine receptors. The method comprises determining a patient's DRD2 genotype. Patients having the Taq1A (A1) allele (A1+ allelic status) are candidates for treatment with high dose, high binding antipsychotics and/or SSRIs that influence D2 receptor density. Patients lacking the Taq1A allele (A1− allelic status) are candidates for treatment with low dose, low binding atypical antipsychotics, and are not likely to respond well to these SSRIs.